CNS myelination and PLP gene dosage

Area of Science:

• Genetics
• Neuroscience
• Genomic Medicine

Background:

• Gene dosage effects are crucial for understanding genetic diseases at the genomic level.
• Classical PCR-based mutation screening fails when only gene copy number, not sequence, is altered.
• Increased gene dosage is a significant mechanism in central (CNS) and peripheral (PNS) nervous system myelin disorders.

Purpose of the Study:

• To review gene dosage effects and mutations of the proteolipid protein (PLP) gene.
• To compare these with peripheral myelin protein 22 (PMP-22) gene dosage effects in neuropathies.
• To explore the implications of gene dosage imbalance for genetic disease and genome rearrangements.

Main Methods:

• Review of literature on PLP and PMP-22 gene dosage effects and mutations.
• Comparison of human genetic disorders with analogous mouse models.
• Focus on submicroscopic duplications leading to increased gene dosage.

Main Results:

• Increased dosage of the PLP gene is the primary cause of Pelizaeus-Merzbacher disease (PMD), often due to Xq22 duplication.
• Dosage effects of PLP and PMP-22 genes underlie CNS and PNS myelination disorders, respectively.
• Submicroscopic genomic duplications and deletions may be underestimated causes of clinical phenotypes.

Conclusions:

• Gene dosage imbalance, particularly duplications, is a key mechanism in neurological disorders.
• Understanding gene dosage effects requires specialized DNA detection techniques beyond sequence analysis.
• Genome sequencing may reveal DNA structural properties predisposing to rearrangements and disease.